Valeant Pharmaceuticals International Inc
Valeant Pharmaceuticals International — Technical Presentation (January 2005)
6 slides from Valeant Pharmaceuticals International's technical presentation, Jan 20, 2005
Slide 1: The Safety and Efficacy of Viramidine in Combination with Peginterferon Alfa-2a for Chronic Hepatitis C
The Safety and Efficacy of Viramidine in Combination with Peginterferon Alfa-2a for the Treatment of Chronic Hepatitis C in Therapy-Naive Patients
Slide 2: Viramidine Phase 2: Patient Demographics and Baseline Characteristics
Viramidine Phase 2: Patient Demographics and Baseline Characteristics PegIFN Alfa-2a + Viramidine PegIFN Alfa-2a + Viramidine PegIFN Alfa-2a + Viramidine PegIFN Alfa-2a + Ribavirin 400 mg BID N=47 600 mg BID N=43 800 mg BID N=45 1,000/1,200 mg N=45 Gender, male 64% 67% 56% 71% Age, mean (SD), yr 47
Slide 3: Viramidine Phase 2: Overall Efficacy
Viramidine Phase 2: Overall Efficacy Percent of Patients with Undetectable HCV RNA* (Intent-to-Treat Analysis) *Bayer TMA Assay; sensitivity to 5 IU/mL, 25 copies/mL
Slide 4: Safety: Incidence of Anemia Anytime During Therapy
Viramidine Phase 2 Safety: Incidence of Anemia Anytime During Therapy Hemoglobin <10g/dL at Anytime During Therapy Viramidine Ribavirin *Adjusted for multiple comparisons 0% 2% 11% 27% P <.001* P <.01* P = NS*
Slide 5: Safety: Incidence of Common Adverse Events
Viramidine Phase 2: Safety Incidence of Common* Adverse Events PegIFN Alfa-2A + Viramidine PegIFN Alfa-2A + Viramidine PegIFN Alfa-2A + Viramidine PegIFN Alfa-2A + Ribavirin 400 mg BID 600 mg BID 800 mg BID 1000/1200 mg Fatigue 81% 84% 84% 76% Headache 72% 67% 60% 71% Nausea 40% 42% 42% 51% Insomnia
Slide 6: Safety: Incidence of Common Adverse Events Graded Moderate to Severe
Viramidine Phase 2: Safety Incidence of Common* Adverse Events Graded Moderate to Severe PegIFN Alfa-2A + Viramidine PegIFN Alfa-2A + Viramidine PegIFN Alfa-2A + Viramidine PegIFN Alfa-2A + Ribavirin 400 mg BID 600 mg BID 800 mg BID 1000/1200 mg Fatigue 30% 42% 38% 47% Depression 15% 26% 29% 31% Ane
Valeant Pharmaceuticals International — Technical Presentation (January 2005) on 6ix